FINANCING OF PRIVATE BIOTECHNOLOGY COMPANIES: $276.12M | ||||
Company | Location |
Date | Amt. (M) |
Details |
Alder Bio- |
Bothell, Wash. |
7/7/06 |
$16 |
The Series B financing was led by H.I.G. Ventures, which was joined in the deal by existing investors Sevin Rosen Funds, Ventures West and WRF Capital |
Ambrx Inc. |
San Diego |
7/5/06 |
$52 |
The Series C financing was led by Apposite and included Glynn Ventures, the Dow Employees' Pension Plan and Union Carbide Employees' Pension Plan, as well as existing investors Tavistock Life Sciences, Maverick Capital, 5AM Ventures, Versant Ventures, Aravis Ventures, CMEA Ventures and Roche Venture Fund |
Astion Pharma |
Copenhagen, Denmark |
7/3/06 |
DKK50 ($8.5) |
Existing investors participated in the financing round |
Concert |
Boston |
7/17/06 |
$10 |
The Series A financing round was co-led by Three Arch Partners, TVM Capital and Skyline Ventures, and included Greylock Partners and QVT Fund LP |
CS-Keys Inc. |
Indianapolis |
7/17/06 |
ND |
Triathlon Medical Ventures provided seed funding for CS-Keys |
Elusys |
Pine Brook, N.J. |
7/13/06 |
$11 |
MedImmune Ventures Inc. joined current investors including Essex Woodlands Health Ventures LLC, Crescendo Ventures and Invesco Private Capital in an extension of the Series D round; the first part of the total $23M round closed in August 2004 |
Kinaxo |
Martinsried, Germany |
7/27/06 |
€0.6 |
Investing in the seed financing round were High-Tech Grunderfonds and company founders |
Kythera Bio- |
Los Angeles |
7/24/06 |
$30 |
The Series B financing round was led by Prospect Venture Partners and ARCH Venture Partners, and included Versant Ventures, Altitude Life Science Ventures, the UCLA Venture Fund and the Wilson Sonsini Goodrich and Rosati Investment Co. |
Lux |
Jersey City, N.J. |
7/19/06 |
$13 |
The company added $13M to a $36M Series A investment made in May, bringing the round's total to $49M; new investor Prospect Venture Partners provided $12M of the new funding |
NanoMed |
Kalamazoo, Mich. |
7/5/06 |
ND |
The Series A financing was led by the SWMF Life Science Venture Fund |
Ocera |
San Diego |
7/10/06 |
$12 |
The Series B financing was led by new investor Sofinnova Ventures, and included previous investors Domain Associates LLC and Thomas, McNerney & Partners LLC |
Paradigm |
Cambridge, UK |
7/7/06 |
£7 ($12.9) |
Participating in the Series D financing were existing investors Avlar BioVentures, Bio*One Capital, Merlin Biosciences and Lloyds TSB Capital Development |
Pathwork |
San Jose, Calif. |
7/6/06 |
$11 |
The company was created through Predicant Biosciences' acquisition of Pathwork Informatics; Venture Partners, Novus Ventures, Venrock investing were Prospect Venture Partners, Advent Associates and Versant Ventures |
Prestwick |
Washington |
7/24/06 |
$30 |
New investor Warburg Pincus led the Series C round, which could increase to $60M if certain conditions are met; existing investors Atlas Venture, BA Venture Partners, CNF Investments, Pequot Ventures, Sofinnova Ventures and Vivo Ventures also participated |
Protiva Bio- |
Vancouver, British Columbia |
7/13/06 |
C$5.6 ($4.95) |
The third-round financing included existing investors the Working Opportunity Fund, BDC Capital, the Canadian Medical Discoveries Fund and Kinetic Capital |
Synta |
Lexington, Mass. |
7/11/06 |
$40 |
A combination of existing and undisclosed new institutional investors participated in the financing round |
Transpharma |
Lod, Israel |
7/24/06 |
$18 |
The Series C financing was led by Argonaut Private Equity and included Teva Pharmaceutical Industries Ltd., Pitango Venture Capital, Evergreen Partners, T2C2/Bio, Vitalife, Biomedical Investments and TIF Ventures Pte. Ltd. |
Xencor Inc. |
Monrovia, Calif. |
7/11/06 |
$6 |
The bridge financing was provided by Novo Nordisk A/S and existing investors; Novo Nordisk also committed to invest another $6M in future Xencor financings |
Notes: | ||||
Currency conversions are based on exchange rates at the time of the deal. | ||||
ND = Not disclosed. | ||||
To read more on related topics, click on one of the words below.